New drug shrinks lung tumors before surgery in targeted trial
NCT ID NCT07156604
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 26 times
Summary
This study tests a drug called Vebreltinib given for 8 weeks before surgery in people with a specific type of lung cancer (stage IIA-IIIB NSCLC with a MET gene change). The goal is to see if the drug can shrink tumors enough to improve surgery outcomes. About 30 participants will take the pill twice daily, then have surgery, and be followed for up to 3 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center, Shanghai,
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.